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P U B L I S H E D B Y E L S E V I E R I N C .LettersNew-Onset Atrial
Fibrillation During
HospitalizationCurrent guidelines (1) acknowledge that atrial ﬁbril-
lation (AF) may be triggered by potentially reversible,
or acute, causes such as surgery (cardiac and
noncardiac), hyperthyroidism, myocarditis or peri-
carditis, myocardial infarction, pulmonary embolism,
pneumonia, and alcohol intoxication. Incidence and
risk for new-onset AF associated with acute condi-
tions are unclear.
We investigated the epidemiology of new-onset AF
associated with acute conditions in a population-
based sample of hospitalized patients using 2011
data from the California State Inpatient Database (2).
We excluded patients <40 years of age, in whom AF
is rare (incidence < 0.1%) (1). We abstracted de-
mographics, comorbidities, and guideline-deﬁned (1)
AF-associated acute conditions using International
Classiﬁcation of Diseases-Ninth Revision-Clinical
Modiﬁcation (ICD-9-CM) codes that were present upon
admission. Because alcohol intoxication generally
resolves at admission, we did not report alcohol-
associated new-onset AF. We identiﬁed new-onset AF
through ICD-9-CMcode427.3 not present on admission.
Surgical procedures were deﬁned by diagnosis-related
group and ICD-9-CM codes. We performed multivar-
iate logistic regression for new-onset AF adjusting for
demographics, comorbid conditions, and acute condi-
tions (Table 1). We conducted analyses investigating
associations between infection site and new-onset
AF and associations between increasing infection
and myocardial infarction severity and new-onset AF.
Procedures were approved by the Boston University
Medical Campus Institutional Review Board.
We identiﬁed 2,275,588 patients hospitalized in
California during 2011. Patients’ mean age was 66  14
years, 53% were women, 61% were white, 9% were
black, 8% were Asian, and 21% were Hispanic. Any AF
diagnosis was present during 342,778 (15%) hospital-
izations, with new-onset AF constituting 22,780 of
the AF cases (6.7%). Of new-onset AF cases, 18,575
(81.5%) were associated with guideline-identiﬁed
acute conditions (1).Table 1 demonstrates the proportion of new-onset
AF cases during hospitalization associated with each
acute condition and the multivariate-adjusted odds
ratio (OR) for risk for new-onset AF associated with
each condition. Most cases of new-onset AF were
associated with noncardiac surgery (37.2% of new-
onset AF) and infection (34.9%). Cardiac surgery
was associated with 21.9% of new-onset AF cases and
conferred a 50-fold increased adjusted odds of AF
compared with other hospitalized patients. Condi-
tions, such as pulmonary embolism, thyrotoxicosis,
and myocarditis or pericarditis, showed modest as-
sociations with new-onset AF (adjusted OR: 1.43 to
1.78) but represented fewer than 2.5% of cases.
Among infectious conditions, pneumonia (12.2% of
new-onset AF; adjusted OR: 2.6), urinary tract infec-
tion (11.6%; adjusted OR: 1.4), and intra-abdominal
infection (10.5%; adjusted OR: 1.6) were associated
with new-onset AF. Greater disease severity was
associated with increased new-onset AF risk (i.e.,
infection alone: OR: 1.30; septic shock: OR: 4.53;
myocardial infarction alone: OR: 1.33; with cardio-
genic shock: OR: 2.3).
Our ﬁndings have implications for acute manage-
ment and post-hospitalization follow-up of patients
with new-onset AF. The majority of new-onset AF
cases occur after noncardiac surgery or in patients
with infections. Thus, most hospitalized patients
with new-onset AF are unlikely to be under the direct
care of cardiologists or cardiac surgeons, who may be
most adept at treating new-onset AF. In addition,
emerging evidence suggests that new-onset AF asso-
ciated with acute conditions, (e.g., sepsis [3]) has high
rates of recurrence and adverse long-term outcomes.
Improved communication of long-term AF risks be-
tween hospital and outpatient providers is warranted.
Our ﬁndings also differ from opinions expressed in
recent guidelines (1). For example, most cases of new-
onset AF occurred in patients admitted with in-
fections or in post-operative patients. Although
pneumonia is explicitly identiﬁed in guidelines as a
condition associated with new-onset AF, infections
from other sources were similarly represented among
cases of new-onset AF. Conditions such as pulmonary
embolism, thyrotoxicosis, and pericarditis were
rarely present among hospitalized patients with new-
onset AF.
TABLE 1 Acute Conditions Associated With New-Onset AF Among Hospitalized Adults
Acute Condition
Number With
New-Onset AF*
(Total N ¼ 22,780)
% New-Onset AF
With Condition*
% Condition
With New-Onset AF
Multivariate-Adjusted†
OR for New-Onset AF
(95% CI)
Noncardiac surgery (n ¼ 641,071) 8,481 37.2 1.3 3.08 (2.99–3.18)
Infection (n ¼ 730,379) 7,944 34.9 1.1 1.54 (1.49–1.59)
Cardiac surgery (n ¼ 23,083) 4,804 21.9 20.8 52.4 (50.2–54.7)
Myocardial infarction (n ¼ 77,848) 2,234 9.8 2.9 1.41 (1.34–1.48)
Pulmonary embolism (n ¼ 20,939) 244 1.1 1.2 1.43 (1.26–1.63)
Thyrotoxicosis (n ¼ 10,172) 141 0.6 1.4 1.78 (1.49–2.12)
Myocarditis or pericarditis (n ¼ 3,705) 126 0.6 3.4 1.73 (1.41–2.12)
*Individual patients may have multiple diagnoses associated with new-onset AF. †Model adjusted for age, race, sex, history of diabetes mellitus, hypertension, heart failure,
chronic pulmonary disease, stroke, metastatic cancer, prior myocardial infarction, and the acute conditions infection, surgery (cardiac and noncardiac), myocardial infarction,
alcohol intoxication, pulmonary embolism, thyrotoxicosis, and myocarditis or pericarditis.
AF ¼ atrial ﬁbrillation; CI ¼ conﬁdence interval; OR ¼ odds ratio.
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2433Our study was limited by the ability of ICD-9-CM
codes to identify temporal proximity between
acute diagnoses and AF, especially when multiple
diagnoses occurred simultaneously. Our results may
not be generalizable outside of hospitalized patients.
We were unable to identify whether AF present at the
time of admission was new or pre-existing, a limita-
tion that may result in underestimates of the associ-
ation between some acute conditions and new-onset
AF. Furthermore, cardiac rhythm monitoring may be
more likely in some clinical scenarios (e.g., after car-
diac surgery), and may have inﬂuenced our results.
In conclusion, we have examined risks for new-
onset AF associated with acute conditions in a
representative sample of hospitalized patients. Our
ﬁndings inform prior knowledge gaps regarding acute
conditions associated with new-onset AF and may
provide targets for improved processes of care.*Allan J. Walkey, MD, MSc
Emelia J. Benjamin, MD, ScM
Steven A. Lubitz, MD, MPH
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Inappropriate and
Nonrecommended
Prasugrel Prescription
Great VariationsWe read with great interest the work by Hira et al. (1)
presenting a high rate of prasugrel prescription with
inappropriate or nonrecommended indications. In
previous studies, prasugrel was prescribed at hospital
discharge despite the presence of at least one con-
traindication in 9.6% of patients, while inappropriate
prasugrel prescription within 24 h of admission was
observed in 1.8% of patients (2,3). Differences in
provider type, data elements collected, and deﬁni-
tions applied may account for these variations, and
this should be highlighted.
No net clinical beneﬁt from prasugrel compared
with clopidogrel has been described, not only in the
subgroup of patients $75 years of age but also in those
with low body weight (<60 kg). Therefore, in the pra-
sugrel package insert, body weight < 60 kg is reported
as a risk factor for bleeding, constituting, in our view, a
nonrecommended indication. It would be interesting
to know the prevalence of patients weighing <60 kg in
the studied population, providing an estimate of how
many additional patients likely received prasugrel for
a nonrecommended indication. Additional risk factors
increasing the risk for bleeding are included in the
black-box warning and have been speciﬁcally reported
to affect nonrecommended selection of prasugrel (4).
Data on prasugrel’s use in patients receiving
concomitant aspirin and warfarin are extremely
important, and it would be very interesting to have
some idea about this subgroup’s outcomes. In a much
